RedHill Biopharma: RHB-107 included in Government-supported COVID-19 trial

RedHill Biopharma announced that RHB-107 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funded by the U.S. Government Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, has received FDA clearance to start and is estimated to be completed by end of 2024.